Healthcare Business Recap: Haemonetics Postpones Hemerus Purchase, Nabi and Biota Modify Agreement
Haemonetics Corp. (NYSE:HAE) reports that its proposed purchase of Hemerus Medical will probably be postponed until March of 2013, after the start of its 2014 fiscal year. It appears that American regulators have requested more information concerning its SOLX whole-blood collection system as a part of the resubmitted marketing application.
Nabi Biopharmaceuticals (NASDAQ:NABI) and its prospective merger partner Biota Holdings have both agreed to modify terms of their agreement, which provides that $27 million is to be divided among NABI shareholders in compensation for Biota’s reduced share value since the transaction was first announced back in April.
Don’t Miss: Are Staph Infection Vaccines on the Cusp?
According to Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), its corporate partner MolecularMD has voluntarily withdrawn its pre-marketing approval application for BCR-ABL T3151, which is a mutation test for diagnosis of certain forms of leukemia, that was to be used in tandem with ARIA’s ponatinib BCR-ABL inhibitor. Ariad was recently informed by the FDA that the test is no longer considered a companion diagnostic test for ponatinib.
Quidel Corporation (NASDAQ:QDEL) attains the CE Mark for its Sofia RSV FIA for use on the Sofia Analyzer for the rapid detection of respiratory syncytial virus. Sofia is the brand name for Quidel’s next generation, immunoassay system which was introduced earlier in 2012. Now, with the CE Mark, the firm is now free to launch the system on the Continent.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>